ArticleAnnals of medicine2026
Cord blood transfusion added matched unrelated donor transplantation as a preferable choice for aplastic anaemia: a comparative study from a single centre.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMatched sibling donors (MSDs) were preferred for haematopoietic stem cell transplantation (HSCT) in severe aplastic anaemia (AA) when lacking MSDs, unrelated donors (URDs) and haploidentical (Haplo) donor would be considered, but limited by increased graft-versus-host disease (GVHD) and recommended only in experienced centres. This study aimed to compare the efficacy and safety of umbilical cord blood transfusion added URD-HSCT (URD-cord-HSCT) to MSD-HSCT and Haplo-HSCT in AA patients.
methodsPatients who underwent URD-cord-HSCT (
resultsNo significant differences in neutrophil and platelet engraftment. The three-year overall survival (OS) rates were 88.0% ± 6.5%, 92.1% ± 5.3% and 74.8% ± 6.0% (
conclusionsMUD-cord-HSCT provides an optimal solution for MC and GVHD, with outcome comparable or even better than those of MSD-HSCT.KEY MESSAGESThe best choice of alternative donor for aplastic anaemia remains a clinical challenge, unrelated donors (URDs) or haploidentical (Haplo) donor?Umbilical cord blood (UCB) transfusion added matched unrelated donor (MUD) haematopoietic stem cell transplantation (HSCT) exert nearly 0% cumulative incidence of mixed chimerism and grade II-IV acute/chronic GVHD;UCB added MUD-HSCT (MUD-cord-HSCT), which exert 100% three-year overall survival (OS) and 85.7% event free survival (EFS), rather than matched sibling donor (MSD)-HSCT, exert superiority in OS and EFS than mismatched URD (MMUD)-HSCT and haploidentical-HSCT.MUD-cord-HSCT provides an optimal solution for MC and GVHD, with outcome comparable or even better than those of MSD-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.